MARKET

XXII

XXII

22ND CENTURY
AMEX

Real-time Quotes | Nasdaq Last Sale

3.460
-0.020
-0.57%
After Hours: 3.500 +0.04 +1.16% 18:54 04/13 EDT
OPEN
3.500
PREV CLOSE
3.480
HIGH
3.540
LOW
3.355
VOLUME
1.43M
TURNOVER
--
52 WEEK HIGH
4.660
52 WEEK LOW
0.5500
MARKET CAP
527.30M
P/E (TTM)
-24.3834
1D
5D
1M
3M
1Y
5Y
Courier Capital Corp Buys Invesco S&P 500 Equal Weight ETF, Invesco BulletShares 2022 ...
GuruFocus News · 1d ago
Cannabis Movers & Shakers: JMP Group, GTI, Curaleaf, Conception Nurseries, Myconic, AMP, Neon, NCR, 22nd Century, cbdMD
JMP Group Appoints Investment Expert Alfredo Barreto To Oversee Its Investment Banking Division
Benzinga · 4d ago
Cannabis Stock Gainers And Losers From April 8, 2021
GAINERS: Primo Nutraceuticals (OTC: BUGVF) shares closed up 50% at $0.15
Benzinga · 5d ago
22nd Century Group Regulatory Science VP Joins FDLI Tobacco and Nicotine Products Committee
Another key indicator and milestone of the Increasing Importance of Reducing Cigarette Nicotine Content as Cornerstone of Public Health PolicyBUFFALO, N.Y., April 08, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-...
GlobeNewswire · 5d ago
22nd Century Group Regulatory Science VP Joins FDLI Tobacco and Nicotine Products Committee
22nd Century Group, Inc. (NYSE:XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that the
Benzinga · 5d ago
8-K: Charlie's Holdings, Inc.
Edgar Online - (EDK = 8-Ks/S1/S-4) · 04/07 03:33
Charlie's Holdings Hires Former 22nd Century Group CEO as President
Henry Sicignano will Spearhead the Company's Business Strategy and Capital Markets Initiatives
ACCESSWIRE · 04/06 21:03
22nd Century Group Says Continues To Be Confident On Renewal Of FDA's Proposed Reduced Nicotine Mandate That Would Make All Cigarettes 'Minimally Or Non-Addictive;' Shares Move Higher
22nd Century Group, Inc. (NYSE:XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it
Benzinga · 04/01 14:08
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XXII. Analyze the recent business situations of 22ND CENTURY through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XXII stock price target is 7.00 with a high estimate of 7.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 110
Institutional Holdings: 35.63M
% Owned: 23.38%
Shares Outstanding: 152.40M
TypeInstitutionsShares
Increased
26
1.15M
New
10
11.16M
Decreased
24
726.16K
Sold Out
14
345.75K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Environmental Services & Equipment
-0.49%
Professional & Commercial Services
+0.23%
Key Executives
Chairman/Director
Nora Sullivan
President/Chief Operating Officer
Michael Zercher
Chief Executive Officer
James Mish
Chief Financial Officer
John Franzino
Vice President
John Brodfuehrer
Vice President
Lisa Parks
Vice President - Research & Development
Juan Tamburrino
Director of Investor Relations
Mei Kuo
Independent Director
Michael Koganov
Independent Director
Roger O'Brien
Independent Director
Richard Sanders
No Data
About XXII
22nd Century Group, Inc. is a plant biotechnology company. The Company is focused on technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. It is engaged in various activities, including research and development of less harmful or modified risk tobacco products and tobacco plant varieties; development of X-22, a smoking cessation aid consisting of very low nicotine (VLN) cigarettes; manufacture, marketing and distribution of its RED SUN and MAGIC cigarettes; production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA); contract manufacturing of third-party branded tobacco products, and research and development of plant varieties of hemp/cannabis, such as plants with low to no amounts of delta-9-tetrahydrocannabinol (THC), plants with high levels of cannabidiol (CBD), and other non-THC cannabinoids.

Webull offers kinds of 22nd Century Group Inc stock information, including AMEX:XXII real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XXII stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XXII stock methods without spending real money on the virtual paper trading platform.